Drugs / U87 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05605197 | Oct 2022 → Dec 2024 | malignant pancreatic neoplasm | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | U87 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05605197 ↗ |
| Modality | Cell therapy | “U87 CAR-T cells” NCT05605197 ↗ |
| Route | Intravenous | “Intravenous injection of U87” NCT05605197 ↗ |